GSK’s DoJ Settlement Links Executive Bonus To Continued Compliance
Executive Summary
GlaxoSmithKline pleads guilty to marketing Paxil and Wellbutrin off-label and concealing Avandia safety data from FDA and resolves allegations of kickbacks involving nine drugs; ground-breaking corporate integrity agreement includes novel recoup of bonuses from execs if they or their subordinates engage in “significant misconduct.”
You may also be interested in...
DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.
FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation
Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.
FDA Polled Review Staff On Avandia REMS Changes
Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.